MetaVia Inc. MTVA
Biotechnology: Pharmaceutical Preparations · IPO 2016 · data as of November 13, 2026
MetaVia Inc. (MTVA) is a healthcare company listed in the US with a market value of about $9M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -179%.
About MetaVia
MetaVia is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2016. It was profitable in 0 of the last 10 years in our data. Its share count rose by 5939% over three years (dilution for shareholders).
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | — |
| Net income | -$13M | -$28M | -$12M | -$14M | -$15M | -$30M | -$21M | -$16M | -$33M | -$15M |
| Free cash flow | -$16M | -$25M | -$11M | — | -$15M | -$11M | -$7M | -$14M | — | — |
| EPS (diluted) | $-7.35 | $-39.13 | $-27.06 | $-477.62 | $-1743.28 | $-4831.44 | $-10771.73 | $-9636.48 | $-8527.62 | $-6785.14 |
| Net margin | — | — | — | — | — | — | — | — | — | — |
| ROIC | -247.3% | -357.1% | -94.1% | -90.2% | -104.3% | -407.2% | -162.6% | — | -132500.0% | -71.2% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 3 analysts is $19.33, 1387% above the current price; targets range from $8.00 to $30.00; the consensus rating is “none”; expected EPS is $-2.52 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does MetaVia pay a dividend?
Not currently.
Is MetaVia a good stock to buy?
We do not give buy or sell advice. MetaVia scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.